Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis

Oncology Reports

Volumn 19, Issue 4, 2008, Pages 1045-1053

  Peng, Shian Yang ^a   Lai, Po Lin ^b   Pan, Hung Wei ^c   Hsiao, Li Pin ^b   Hsu, Hey Chi ^b,c  

^a NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Aldolase B; Early tumor recurrence; Hepatocellular carcinoma; Portal vein invasion; Prognosis; Type II hexokinase

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; FRUCTOSE BISPHOSPHATE ALDOLASE; HEXOKINASE; MESSENGER RNA; MUTANT PROTEIN; PROTEIN P53;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEFECT; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MOTIF; SURVIVAL TIME; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FRUCTOSE-BISPHOSPHATE ALDOLASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, P53; HEXOKINASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER;

EID: 43849113286     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.4.1045     Document Type: Article

References (50)

1. Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995.
2. Guillemin K and Krasnow MA: The hypoxic response: huffing and HIFing. Cell 89: 9-12, 1997.
3. Warburg O: On respiratory impairment in cancer cells. Science 124: 269-270, 1956.
4. Haussinger D and Schliess F: Glutamine metabolism and signaling in the liver. Front Biosci 12: 371-391, 2007.
5. Beckner ME, Stracke ML, Liotta LA and Schiffmann E: Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst 82: 1836-1840, 1990.
6. Greiner EF, Guppy M and Brand K: Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J Biol Chem 269: 31484-31490, 1994.
7. Dang CV and Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72, 1999.
8. Selak MA, Armour SM, MacKenzie ED, et al: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7: 77-85, 2005.
9. Gottlieb E and Tomlinson LP: Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev 5: 857-866, 2005.
10. Green DR and Chipuk JE: p53 and metabolism: Inside the TIGAR. Cell 126: 30-32, 2006.
11. Glass-Marmor L and Beitner R: Detachment of glycolytic enzymes from cytoskeleton of melanoma cells induced by calmodulin antagonists. Eur J Pharmacol 328: 241-248, 1997.
12. Schwartz D and Beitner R: Detachment of the glycolytic enzymes, phosphofructokinase and aldolase, from cytoskeleton of melanoma cells, induced by local anesthetics. Mol Genet Metab 69: 159-164, 2000.
13. Bozzetti F, Gavazzi C, Mariani L and Crippa F: Glucose-based total parenteral nutrition does not stimulate glucose uptake by human tumours. Clin Nutr 23: 417-421, 2004.
14. Tatsumi M, Nakamoto Y, Traughber B, Marshall LT, Geschwind JF and Wahl RL: Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18] fluoro-2-deoxy-D-glucose. Cancer Res 63: 6252-6257, 2003.
15. Fukuda K, Taniguchi H, Koh T, Kunishima S and Yamagishi H: Relationships between oxygen and glucose metabolism in human liver tumours: positron emission tomography using (15)O and (18)F-deoxyglucose. Nucl Med Commun 25: 577-583, 2004.
16. Chen CJ, You SL, Lin LH, Hsu WL and Yang YW: Cancer epidemiology and control in Taiwan: A brief review. Jpn J Clin Oncol 32: 566-S81, 2002.
17. Schafer D, Hamm-Kunzelmann B and Brand K: Glucose regulates the promoter activity of aldolase A and pyruvate kinase M2 via dephosphorylation of Sp1. FEBS Lett 417: 325-328, 1997.
18. Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M and Esumi H: Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 21: 6082-6090, 2002.
19. Izuishi K, Kato K, Ogura T, Kinoshita T and Esumi H: Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res 60: 6201-6207, 2000.
20. Mathupala SP, Rempel A and Pedersen PL: Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276: 43407-43412, 2001.
21. Mathupala SP, Rempel A and Pedersen PL: Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 270: 16918-16925, 1995.
22. Goel A, Mathupala SP and Pedersen PL: Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 278: 15333-15340, 2003.
23. Rempel A, Bannasch P and Mayer D: Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta 1219: 660-668, 1994.
24. Shinohara Y, Ichihara J and Terada H: Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130. FEBS Lett 291: 55-57, 1991.
25. Rose IA and Warms JV: Stability of hexokinase II in vitro and in ascites tumor cells. Arch Biochem Biophys 213: 625-634, 1982.
26. Yasuda S, Arii S, Mon A, et al: Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol 40: 117-123, 2004.
27. Rempel A, Mathupala SP, Griffin CA, Hawkins AL and Pedersen PL: Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res 56: 2468-2471, 1996.
28. Mathupala SF, Heese C and Pedersen PL: Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272: 22776-22780, 1997.
29. Izzo P, Costanzo P, Lupo A and Salvatore F: Novel Aspects of the Human Aldolase Gene Family and its Expression in Tumor Cells. In: Human tumor markers. Cimino F, Birkmayer GD, Klavins JV, Pimentel E and Salvatore F (eds). Walter de Gruyter, Berlin, pp889-898, 1987.
30. Asaka M, Kimura T, Meguro T, Kato M, Kudo M, Miyazaki T and Alpert E: Alteration of aldolase isozymes in serum and tissues of patients with cancer and other diseases. J Clin Lab Anal 8: 144-148, 1994.
31. Motomura M, Mukai T, Ozaki I, Joh K, Arai Y, Sakai T and Hori K: Transcriptional regulation of an aldolase gene in the regenerating rat liver. Jpn Gastroenterol 25: 350-355, 1990.
32. Bustamante E, Morris HP and Pedersen PL: Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 256: 8699-8704, 1981.
33. Kinoshita M and Miyata M: Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci. Hepatology 36: 433-438, 2002.
34. Hsu HC, Chiou TJ, Chen JY, Lee CS, Lee PH and Peng SY: Clona]ity and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology 13: 923-928, 1991.
35. Pan HW, Ou YH, Peng SY, et al: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98: 119-127, 2003.
36. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC and Hsu HC: High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 112: 44-50, 2004.
37. Pan HW, Chou HY, Liu SH, Peng SY, Liu CL and Hsu HC: Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle 5: 2676-2687, 2006.
38. Yuan RH, Jeng YM, Chen HL, et al: Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209: 549-558, 2006.
39. Hsu HC, Tseng HJ, Lai PL, Lee PH and Peng SY: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 53: 4691-4694, 1993.
40. Hsu HC, Peng SY, Lai PL, Chu JS and Lee PH: Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis. Int J Oncol 4: 1341-1347, 1994.
41. Hu RH, Lee PH, Yu SC, et al: Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 120: 23-29, 1996.
42. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL and Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89: 500-507, 2000.
43. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW and Gores GJ: Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 42: 358-364, 2005.
44. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
45. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
46. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
47. Zhang W, Shay JW and Deisseroth A: Inactive p53 mutants may enhance the transcriptional activity of wild-type p53. Cancer Res 53: 4772-4775, 1993.
48. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL and Koeffler HP: Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9: 1899-1906, 1994.
49. Koonin EV, Rogozin IB and Glazko GV: p53 gain-of-function: tumor biology and bioinformatics come together. Cell Cycle 4: 686-688, 2005.
50. Di Agostino S, Strano S, Emiliozzi V, et al: Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191-202, 2006.